AiCuris: AiCuris Anti-infective Cures AG: AiCuris Received 15 Million Euros Milestone Payment from Licensing Partner MSD Following EMA Approval of PREVYMIS for Prevention of CMV Infection in High-Risk Adult Kidney Transplant Recipients
PREVYMIS® now approved in the U.S. and Europe for prophylaxis of Cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative ...
Read full article »
AiCuris is a Germany-based pharmaceutical company that discovers, researches and develops antiviral and antibacterial agents for the treatment of infectious diseases.
Read more